Regrow

Quick links to important sections

Regrow

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regrow

Regrow: An Overview of the Drug's Identity

Property Description
Active Ingredient Minoxidil
Common Forms Topical solution, topical foam
Pharmacological Class Vasodilator, Potassium Channel Opener
Origin Synthetic compound
General Purpose Stabilize and promote hair growth

Regrow is a recognized brand of the medication Minoxidil, a synthetic compound that belongs to the vasodilator class of drugs. This medicine is primarily formulated as an over-the-counter (OTC) topical solution or foam intended for direct application to the scalp. Minoxidil was historically developed as an oral prescription drug for the treatment of severe high blood pressure, but its subsequent use as a topical hair growth promoter is now clinically recognized across multiple health jurisdictions.


What Is Regrow's Pharmacological Class and Composition?

Regrow's composition is based on the active ingredient Minoxidil, typically supplied at 2% or 5% concentrations. The key active agent is classified pharmacologically as a potassium channel opener. This classification assures patients that the medicine works via a confirmed, well-studied biochemical pathway.

The choice between the liquid solution, which often contains propylene glycol to aid in absorption, and the foam formulation is a primary differentiator among Minoxidil brands. The foam formulation is frequently preferred by users with sensitive skin or those looking for an easier product to integrate into a daily routine.


Primary Therapeutic Purpose and Patient Focus

The fundamental therapeutic purpose of Regrow is to stabilize hair loss and stimulate new hair growth in adults experiencing androgenetic alopecia (pattern hair loss). The 5% strength is generally focused on men, while the 2% strength is commonly marketed toward women, reflecting the clinical recognition of different concentration needs for specific patient groups. The overall goal of therapy is consistent: to help reverse the miniaturization of hair follicles and maintain visible hair density.

Regulatory References

  1. Minoxidil - StatPearls - NCBI Bookshelf
  2. Androgenetic Alopecia - StatPearls - NCBI Bookshelf

What side effects are possible with Regrow?

Possible Side Effects and Safety Information

The official safety profile for Regrow (topical Minoxidil) is primarily characterized by localized reactions at the application site and the potential, though rare, for systemic effects if absorption exceeds expected levels, as outlined in government regulatory documents.

Adverse Reaction Classification

Side effects are categorized based on their frequency of occurrence documented in regulatory labeling:

  • Common Reactions: The most frequently reported adverse events are local dermatological issues. These include scalp irritation (such as itching, dryness, or erythema) and hypertrichosis (unwanted hair growth in non-scalp areas). The initial increase in hair shedding is also a documented, typically transient, occurrence at the start of treatment.

  • Less Common Systemic Reactions: When systemic absorption occurs, less frequent effects such as headache, lightheadedness, and dizziness may appear.

Serious Adverse Reactions

Serious adverse reactions, which are generally linked to excessive systemic absorption, are documented in official prescribing information:

  • Cardiovascular and Fluid Retention Events: These include signs of systemic hypotension or cardiotoxicity, such as chest pain, rapid or irregular heartbeat (palpitations), and episodes of fainting (syncope). Significant unexplained weight gain or swelling (edema) of the face, hands, or lower legs are also noted as possible serious adverse reactions.

Population and Usage Safety Notes

The regulatory safety profile includes specific considerations for certain groups and usage conditions:

  • Pediatric Use: The safety and effectiveness have not been established for individuals under 18 years of age.
  • Pre-existing Conditions: Caution is advised for patients with a history of heart disease or hypertension, as excessive systemic absorption of Minoxidil could potentially exacerbate these conditions.
  • Application Restrictions: The risk of systemic adverse reactions is increased if the product is applied to a scalp that is irritated, sunburned, broken, or painful, facilitating higher drug absorption into the body.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from Regrow (Topical Minoxidil) is primarily associated with symptoms resulting from systemic absorption following accidental ingestion or application of excessive amounts. These manifestations reflect the drug’s vasodilatory effects, which can be severe.

Officially documented clinical signs of overdose include cardiovascular effects such as hypotension (low blood pressure) and tachycardia (rapid heartbeat). Other reported manifestations are dizziness, faintness, chest pain, lethargy, and fluid retention, which may appear as sudden unexplained weight gain or swollen hands or feet.

Accidental ingestion carries the potential for serious cardiac adverse events and systemic toxicity. Due to this risk, the regulatory instruction is to seek professional assistance or contact a Poison Control Center immediately in the event of accidental ingestion.

Urgent medical help must be sought if any sign of systemic absorption is observed, including chest pain, rapid heartbeat, faintness or dizziness, or unexplained swelling. The product is not for use in children under 18 years, and pediatric ingestion is a defined risk factor.

Management of overdose is symptomatic and supportive, as no specific antidote is known. Officially described clinical procedures include the intravenous administration of normal saline for symptomatic hypotension and the use of a beta-adrenergic blocking agent to manage clinically significant tachycardia.

Therapeutic Uses of Regrow

What Regrow Treats: Main Uses and Benefits

Regrow (Minoxidil) is generally used as a focused dermatological therapy to manage the progressive nature of androgenetic alopecia (pattern hair loss) in adults. The medication may be used to help stimulate hair growth and may assist with slowing the balding process. This therapy is relevant for addressing chronic conditions presenting with symptoms of hair follicle miniaturization, diffuse hair thinning at the crown, and loss of visible hair density. It is typically applied in situations where male-pattern or female-pattern hair loss is present.


Stabilizing Hair Thinning and Improving Density

This therapy is relevant for managing symptom clusters that create noticeable functional strain. By encouraging growth, the medication provides supportive therapeutic benefits that may support improvements in the cosmetic appearance and fullness of the hair. This therapy assists patients with coping more steadily with the visual impact of progressive thinning. Regrow is relevant for patterns of thinning, as opposed to symptoms associated with temporary shedding (like telogen effluvium) or immune-mediated disorders.

Quick Fact: Relief for Progressive Hair Thinning

The therapeutic approach is generally to help stabilize the rate of hair loss and encourage new growth in areas affected by hereditary thinning, which may contribute to supporting functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Regrow (Minoxidil topical) is strictly defined by regulatory authorities and centers on age, underlying health, and the cause of hair loss. Use is established for adults 18 years and older who are experiencing hereditary hair loss (androgenetic alopecia).


Contraindications and Restrictions

Official labeling mandates that Regrow must not be used in certain populations to prevent potential systemic effects or local reactions.

  • Age: The medicine is contraindicated in children and adolescents under 18 years. Use is also often not recommended for adults over 65, as safety and efficacy data is not sufficiently established for these age groups.
  • Health Conditions: Use is contraindicated for individuals with known treated or untreated arterial hypertension and certain cardiovascular diseases (such as coronary insufficiency), due to the risk of systemic absorption.
  • Pregnancy & Lactation: Regrow is contraindicated for women who are pregnant or breastfeeding.
  • Scalp Integrity: The medicine is contraindicated on an abnormal, irritated, infected, inflamed, or sunburned scalp. It must not be used for hair loss that is not hereditary (e.g., sudden, patchy, or related to childbirth).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Regrow (topical Minoxidil) is defined by two primary regulatory domains: substances that alter its absorption through the skin and medications that may have additive systemic effects.

A mandatory restriction exists against the concurrent use of any other topical medicine or preparation on the scalp. This prohibition is in place because certain agents, such as Tretinoin or Anthralin, are officially documented to increase the percutaneous absorption of Minoxidil, thereby raising the risk of systemic exposure. Conversely, other agents like Betamethasone Dipropionate are noted in regulatory documents for potentially decreasing systemic absorption.

When Minoxidil is absorbed systemically, there is an official caution regarding pharmacodynamic interactions. It carries a theoretical possibility of potentiating orthostatic hypotension or having an additive blood-pressure lowering effect when co-administered with classes like Peripheral Vasodilators and Antihypertensive Agents. Specific drugs, including Guanethidine and Betanidine, are cited for this risk. This potential for systemic interaction is of higher clinical significance for individuals with underlying cardiovascular dysfunction.

Other officially documented interactions include the risk that Systemic Cyclosporine may exacerbate hypertrichosis. Co-administration with Low-dose Acetylsalicylic Acid (Aspirin) may diminish the therapeutic effectiveness of the product, and Ethanol (Alcohol) may contribute to additive blood pressure-lowering effects.

Mechanism of Action

The drug Regrow functions as a specific inhibitor targeting the enzyme Prostaglandin G/H synthase 1 and an inducer that interacts with the ATP-sensitive inward rectifier potassium channel 1 (KATP channel). Regrow, which is metabolically converted to its active metabolite, minoxidil sulfate, primarily modulates the function of vascular smooth muscle cells. The minoxidil sulfate metabolite acts as an inducer to open the KATP channels on the plasma membrane of these cells. This opening facilitates an efflux of potassium ions (K^+), leading to hyperpolarization of the cell membrane. The hyperpolarization subsequently inhibits the voltage-gated calcium channels, resulting in a decrease in intracellular calcium ion concentration (Ca^2+). This intracellular consequence causes the relaxation of vascular smooth muscle cells, which reduces peripheral vascular resistance. In dermal papillary cells, the compound exhibits non-channel-related effects. It is thought to activate the extracellular signal-regulated kinase (ERK) and Akt pathways. This activation promotes cellular proliferation and exerts an anti-apoptotic effect by increasing the Bcl-2/Bax ratio. This cascade modulates cell fate toward a state of survival and expansion.

Dosage and Administration Information

How to Use Regrow

The usage of Regrow (Minoxidil) is defined by instructions that dictate the precise application, frequency, and duration of the topical regimen. This medicine is strictly administered via cutaneous application to the scalp.

Official Administration Guidelines

Administration Scope Detail
Route of administration Cutaneous (topical) application to the scalp.
Dosing schedule Application of 1 mL of the solution or half a capful of the foam per use. The maximum total daily dose should not exceed 2 mL of the 5% concentration.
Frequency pattern Twice daily, spaced by approximately 12 hours.

Labeled Usage Constraints and Population Rules

Regrow is formulated in different strengths for general use in specific patient populations. The 5% strength is typically used by men, while the 2% strength is generally used by women for pattern hair loss. The preparation must be applied only to a completely dry scalp and dry hair, and hands must be washed thoroughly immediately following application to prevent unwanted transfer.

Special Procedural Conditions Detail
Preparation requirements Apply only to a completely dry scalp and dry hair.
Missed-dose rule Resume the regimen at the next scheduled time; do not double the next application.
Duration of use The regimen is intended for continuous, long-term use, as cessation of application will lead to the loss of hair that grew in response to treatment.

This protocol defines the standardized, sustained approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Chronic Pain Explorations

Research has explored the drug's activity in models or cohorts associated with chronic pain. Studies investigated whether participants who received the compound exhibited changes in reported pain severity, using tools such as the VAS or NRS.

Research protocols also assessed whether the compound impacted the frequency of reported flare-ups.


Comparison to Other Regimens

Research explored outcomes in cohorts receiving combination therapy versus those receiving monotherapy. Further studies have been conducted to investigate the compound’s effects in conditions characterized by severe inflammation. Research protocols involved monitoring participants across various timeframes, including extended periods in adult cohorts.


Populations Studied

Studies included participants with various health histories, such as a history of cardiovascular issues, to examine potential differences in recorded outcomes. Research has been conducted primarily within adult populations, and evidence remains limited regarding effects in pediatric patient groups.

Note on Interpretation: This summary strictly describes the nature of the research that has been conducted and should not be interpreted as clinical advice or a guarantee of individual patient outcomes.

Frequently Asked Questions (FAQ)

Common questions about Regrow (FAQ)

Q: How quickly should I expect to see any results from taking Regrow?

A: According to official product information, visible results may be observed as early as two months with consistent application, as directed. For some individuals, however, it may take at least four months of continuous use before any hair regrowth is noticeable. Continued use is required to maintain the new hair growth.


Q: Is Regrow safe for people who have liver problems?

A: Regulatory documents advise patients who have or have ever had liver disease to inform their healthcare provider before using Regrow. This step ensures that the medical necessity and appropriateness of the treatment are reviewed based on the patient's full medical history.


Q: Are there any studies showing how Regrow works in the long term?

A: Clinical trials have evaluated the sustained effectiveness of Minoxidil for periods up to 48 weeks with continuous treatment. Official information indicates that consistent hair regrowth was maintained throughout this duration while the product was actively in use.


Q: Does Regrow have any known interactions with herbal supplements like St. John's Wort?

A: Regulatory documents emphasize the importance of sharing a complete list of all products being used, including vitamins, nutritional supplements, and herbal products, with a healthcare professional. This helps assess the risk of potential interactions.


Q: Will taking Regrow make me gain weight?

A: Sudden, unexplained weight gain is listed in the regulatory documents as a serious adverse reaction, potentially related to fluid retention. The product label includes a warning that users should stop the application and seek medical attention if this symptom occurs.


Q: Why do doctors prescribe Regrow for this condition?

A: Regrow is primarily an over-the-counter (OTC) medicine; however, healthcare providers may recommend its use because it contains Minoxidil, an active ingredient recognized to stabilize and stimulate hair growth in adults with pattern hair loss (androgenetic alopecia).


Q: Is Regrow known to cause dry skin or acne?

A: Adverse events reported in official documentation primarily include local scalp irritation, which can include dryness, flaking, or itching at the application site. Acne is not listed as a common or systemic side effect in the regulatory labeling.


Q: What is the longest period of time someone has safely used Regrow?

A: Clinical data supporting hair regrowth and safety has been shown for periods up to 48 weeks of continuous treatment. Due to the chronic nature of the condition, continued long-term use is typically required to maintain the benefit.


Q: Does Regrow affect fertility in men or women?

A: Official labeling confirms the product should not be used during pregnancy or breast-feeding due to potential risk. However, specific data or warnings regarding the drug’s direct effect on general fertility is not detailed in the product information.


Q: Is it safe to use other topical products on the scalp while using Regrow?

A: Official labeling strongly advises against applying any other topical medicines or preparations to the scalp while using Regrow. This caution is because certain products are known to increase the absorption of Minoxidil into the body, thereby raising the risk of systemic exposure.


Q: Are there any specific tests I need before starting Regrow?

A: The official labeling advises individuals to consult with a doctor, especially if they have heart disease, to determine appropriateness for use. This check helps ensure underlying medical conditions are considered before starting the product.


Q: Are there any specific vitamins or minerals that shouldn't be taken with Regrow?

A: Regulatory documents generally recommend informing a healthcare professional about all vitamins, minerals, and supplements being used. This practice helps assess the risk of potential interactions, even if specific micronutrients are not explicitly named as contraindications.


Q: What's the typical time frame for the drug to reach its full effect?

A: While initial results can appear within two months, official information confirms that it may take at least four months for the product to show visible results. Since the treatment is for a chronic condition, ongoing use is necessary to maintain the effect achieved.


Q: Are there any warnings about driving or operating machinery while taking Regrow?

A: The product label lists systemic side effects such as dizziness and faintness (syncope). If these effects occur, they may temporarily impair judgment or coordination.


Q: What are the serious, but rare, side effects of Regrow I should be aware of?

A: The product label lists serious adverse reactions that are warnings to stop use and seek immediate medical attention, including chest pain, a rapid or irregular heartbeat, faintness or dizziness, significant sudden weight gain, and swelling of the hands or feet.


Q: What should I do if I forget to take a dose of Regrow?

A: Official product directions advise against applying a double dose to compensate for a missed application. The regimen should be resumed at the next scheduled time as directed in the product instructions.


Q: Is Regrow considered a long-term treatment?

A: Yes, regulatory information indicates that Regrow is intended for continuous, long-term use. This is because any hair that grows in response to the treatment will be lost if the application is stopped.


Q: Can I drink alcohol while I am taking Regrow?

A: Regulatory interaction documents caution that alcohol (ethanol) may contribute to additive blood pressure-lowering effects when used at the same time as topical Minoxidil.


Q: Does Regrow need to be taken with food, or can it be taken on an empty stomach?

A: Regrow is a topical solution or foam applied externally to the scalp, not an oral medication. Therefore, instructions regarding taking the product with or without food do not apply.


Q: Why does the packaging for Regrow have a specific warning about certain groups of people?

A: Official product packaging includes warnings and contraindications for specific groups, such as individuals under 18 or those with existing heart conditions. These warnings are mandatory to prevent the use of the product in populations where the risk of serious side effects from systemic absorption is elevated.


Q: Are there any known issues with taking Regrow on a flight?

A: The official product labeling states that Regrow is extremely flammable. This caution is in place to warn users to avoid fire, flame, or smoking during and immediately after application, which is a key safety instruction.

How should Regrow be stored and disposed of?

The official labeling for Regrow (minoxidil topical solution) specifies mandatory conditions for storage and disposal to ensure product integrity and safety.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature: 20°C to 25°C (68°F to 77°F).
Environment Protect from excessive heat and open flame, as the solution is flammable.
Container Keep tightly closed and store in the original container.
Safety Store out of the sight and reach of children and pets.

Disposal

Disposal of any unused or expired Regrow must be carried out according to local requirements. Patients are generally instructed not to discard medication via household wastewater unless specifically authorized by local waste management guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Regrow found in:

A-Z Index: